A detailed history of Virtus ETF Advisers LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 2,417 shares of NBIX stock, worth $307,224. This represents 0.14% of its overall portfolio holdings.

Number of Shares
2,417
Previous 2,417 -0.0%
Holding current value
$307,224
Previous $332,000 16.27%
% of portfolio
0.14%
Previous 0.17%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$130.86 - $143.19 $94,611 - $103,526
-723 Reduced 23.03%
2,417 $332,000
Q1 2024

May 15, 2024

BUY
$130.4 - $143.74 $58,940 - $64,970
452 Added 16.82%
3,140 $433,000
Q4 2023

Feb 15, 2024

SELL
$106.07 - $132.76 $57,171 - $71,557
-539 Reduced 16.7%
2,688 $354,000
Q3 2023

Nov 07, 2023

SELL
$94.02 - $117.1 $39,488 - $49,182
-420 Reduced 11.52%
3,227 $363,000
Q2 2023

Aug 14, 2023

BUY
$89.53 - $104.87 $95,080 - $111,371
1,062 Added 41.08%
3,647 $343,000
Q1 2023

May 15, 2023

BUY
$94.11 - $123.02 $4,517 - $5,904
48 Added 1.89%
2,585 $261,000
Q4 2022

Feb 14, 2023

SELL
$106.72 - $127.06 $4,802 - $5,717
-45 Reduced 1.74%
2,537 $303,000
Q3 2022

Nov 14, 2022

BUY
$92.03 - $107.81 $3,497 - $4,096
38 Added 1.49%
2,582 $274,000
Q2 2022

Aug 12, 2022

SELL
$75.79 - $100.07 $148,017 - $195,436
-1,953 Reduced 43.43%
2,544 $248,000
Q4 2021

Feb 14, 2022

SELL
$79.65 - $106.22 $7,726 - $10,303
-97 Reduced 2.11%
4,497 $383,000
Q3 2021

Nov 15, 2021

SELL
$86.18 - $99.03 $36,023 - $41,394
-418 Reduced 8.34%
4,594 $441,000
Q2 2021

Aug 10, 2021

SELL
$89.43 - $102.27 $150,242 - $171,813
-1,680 Reduced 25.1%
5,012 $488,000
Q1 2021

May 17, 2021

BUY
$87.57 - $119.4 $15,762 - $21,492
180 Added 2.76%
6,692 $651,000
Q4 2020

Feb 12, 2021

BUY
$86.91 - $108.33 $123,499 - $153,936
1,421 Added 27.91%
6,512 $624,000
Q3 2020

Nov 13, 2020

BUY
$96.16 - $135.15 $27,309 - $38,382
284 Added 5.91%
5,091 $490,000
Q2 2020

Aug 05, 2020

SELL
$85.09 - $130.36 $43,821 - $67,135
-515 Reduced 9.68%
4,807 $587,000
Q1 2020

May 14, 2020

SELL
$75.11 - $113.76 $33,724 - $51,078
-449 Reduced 7.78%
5,322 $461,000
Q4 2019

Feb 13, 2020

SELL
$86.8 - $118.57 $215,177 - $293,935
-2,479 Reduced 30.05%
5,771 $620,000
Q3 2019

Nov 12, 2019

SELL
$83.82 - $101.5 $117,012 - $141,694
-1,396 Reduced 14.47%
8,250 $743,000
Q2 2019

Aug 13, 2019

SELL
$72.24 - $91.27 $74,046 - $93,551
-1,025 Reduced 9.61%
9,646 $814,000
Q1 2019

May 14, 2019

BUY
$69.31 - $91.53 $165,373 - $218,390
2,386 Added 28.8%
10,671 $940,000
Q4 2018

Feb 05, 2019

BUY
$68.32 - $124.36 $31,563 - $57,454
462 Added 5.91%
8,285 $592,000
Q3 2018

Nov 14, 2018

BUY
$98.88 - $125.85 $52,109 - $66,322
527 Added 7.22%
7,823 $962,000
Q2 2018

Aug 10, 2018

SELL
$75.3 - $105.99 $421,905 - $593,861
-5,603 Reduced 43.44%
7,296 $717,000
Q1 2018

May 14, 2018

SELL
$75.88 - $92.43 $57,137 - $69,599
-753 Reduced 5.52%
12,899 $1.07 Million
Q4 2017

Feb 14, 2018

SELL
$58.53 - $77.59 $579,388 - $768,063
-9,899 Reduced 42.03%
13,652 $1.06 Million
Q2 2017

Aug 14, 2017

BUY
N/A
23,551
23,551 $1.08 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12.2B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.